Core Insights - Hoth Therapeutics has integrated OpenAI API to enhance the development of its orphan-designated therapy HT-KIT, aimed at treating rare KIT-driven cancers [1] - The company is progressing towards Investigational New Drug (IND) submission and Phase 1 clinical evaluation for HT-KIT, which has shown promising results in preclinical studies [1] Development Progress - HT-KIT has received Orphan Drug Designation and targets cancers driven by KIT mutations, addressing a significant unmet medical need [1] - The therapy has demonstrated rapid anti-tumor activity, with statistically significant tumor-volume reduction observed by Day 8 in xenograft models [1] - No dose-limiting toxicities have been reported in early studies, indicating favorable tolerability [1] Technical Achievements - The integration of OpenAI's API supports preclinical data analysis, molecular modeling of KIT-driven pathways, and regulatory documentation preparation for IND submission [1] - HT-KIT achieved over 80% reduction of KIT mRNA/protein in both in-vitro systems and in vivo models of systemic mastocytosis and GIST [1]